Wednesday, July 19, 2017 7:12:21 PM
Through its subsidiary Growblox Life Sciences formed last July, the company isplanning pilot human studies in Nevada for two formulations for Parkinson’s disease and chronic pain, respectively, with future IND-enabled clinical trials in other states; while another cardiovascular candidate will be directly put to FDA-registered IND after preclinical studies.
Sales of whole marijuana for nonmedical use have been legalized in Nevada since July 1 after state legislators passed a bill last November, while access to medicinal cannabis allowed among people with certain conditions within the state dates back to 2001.
Instead of whole plants, the drug candidates that the life sciences arm of GB Sciences develops are actually extractions. The company touts that its chronic pain and Parkinson’s formulations do not contain delta-9 tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana, and thus are less likely to be abused.
Previously known as Growblox Sciences until a name change last December, GB filed its first patent applications to the U.S. Patent and Trademark Office last October. The application covers cannabis-derived mixtures of formulations for neuroprotection, intended for treating neurodegenerative diseases like Parkinson’s, Alzheimer’s and Huntington’s. The company later filed two more patent applications: one in February, covering cannabinoid therapies for inflammatory disorders, and another one in May for myrcene-containing mixtures for chronic pain and heart diseases.
After scientific validation and market analysis, the cannabis specialist has decided to first pursue the development of three selected formulations out of all 26 it has. Worldwide will provide pre-IND consulting services, led by Michael Murphy, M.D. Ph.D., the CRO’s chief medical and scientific officer, who was instrumental in selecting the top formulations from GB Sciences’ growing portfolio.
That doesn’t mean GB Sciences intends to manage the studies on its own. Worldwide is bidding on the pilot trials and some of the preclinical work on cardiovascular indications, GB Sciences’ CSO Andrea Small-Howard, Ph.D., told FierceBiotech. She said that GB is also taking bids from other CROs over the next few months to try to find the perfect matches in different therapeutic areas, but added that Worldwide will likely be among the finalists given their close relationship.
“Worldwide has been instrumental in establishing our clinical trial designs across multiple disease categories,” said Small-Howard. “They have breadth of clinical expertise in their team that is unparalleled among CROs working with small companies.”
http://www.fiercebiotech.com/cro/gb-sciences-to-test-cannabis-based-therapies-human-taps-worldwide-clinical-trials
Recent GBLX News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/30/2024 09:13:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 07:12:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM